Pyrazinamide-BSA is an antigen-adjuvant conjugate composed of Pyrazinamide and bovine serum albumin (BSA). This conjugation enhances the production of antigen-specific antibodies in vaccine models by linking the antigen to a protein adjuvant. The conjugate maintains protein folding, preserves major epitopes, and promotes cross-presentation and antigen-specific T cell production.